ROSSANA RONCATO^1,2, JERRY POLESEL³, FEDERICA TOSI^4,5,*, ELENA PERUZZI^1,*, ERIKA BRUGUGNOLI⁶, CLAUDIA LAURIA PANTANO⁷, MARIA FURFARO⁸, FILIPPO DI GIROLAMO^9,10, ALESSANDRO NANI¹¹, ARIANNA PANI⁴, NOEMI MILAN¹, ELENA DE MATTIA¹, ANDREA SARTORE-BIANCHI^4,5, ERIKA CECCHIN¹

Oncology Research, Vol.32, No.9, pp. 1407-1422, 2024, DOI:10.32604/or.2024.049181 - 23 August 2024

Abstract Objectives: Treatment of metastatic colorectal cancer (mCRC) includes resection of liver metastases (LM), however, no validated biomarker identifies patients most likely to benefit from this procedure. This meta-analysis aimed to assess the impact of the most relevant molecular alterations in cancer-related genes of CRC (i.e., RAS, BRAF, SMAD4, PIK3CA) as prognostic markers of survival and disease recurrence in patients with mCRC surgically treated by LM resection. Methods: A systematic literature review was performed to identify studies reporting data regarding survival and/or recurrence in patients that underwent complete liver resection for CRC LM, stratified according to… More > Graphic Abstract

SUNG HEE LIM^1,#, HEE JIN CHO^1,2,3,#, KYOUNG-MEE KIM⁴, HO YEONG LIM¹, WON KI KANG¹, JEEYUN LEE¹, YOUNG SUK PARK¹, HEE CHEOL KIM^5,*, SEUNG TAE KIM^1,*

Oncology Research, Vol.31, No.6, pp. 855-866, 2023, DOI:10.32604/or.2023.030374 - 15 September 2023

Abstract Background: Although bevacizumab is an important treatment for metastatic colorectal cancer (CRC), not all patients with CRC benefit from it; in unselected patient populations, only modest survival benefits have been reported. Methods: We evaluated clinical outcomes in 110 patients using comprehensive molecular characterization to identify biomarkers for a response to bevacizumab-containing treatment. The molecular analysis comprised whole-exome sequencing, ribonucleic acid sequencing, and a methylation array on patient tissues. Results: Genomic and molecular characterization was successfully conducted in 103 patients. Six of 103 CRC samples were hypermutated, and none of the non-hypermutant tumors were microsatellite unstable. Among… More >

YUNG-SUNG YEH^1,2,3, HSIANG-LIN TSAI^4,5, YEN-CHENG CHEN^4,6, WEI-CHIH SU^4,6, PO-JUNG CHEN^4,6, TSUNG-KUN CHANG^4,6,7, CHING-CHUN LI⁴, CHING-WEN HUANG^4,5, JAW-YUAN WANG^{4,5,6,8,9,10,*}

Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659 - 05 January 2023

Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response,… More >

Hsiang-Lin Tsai^*†, Yen-Cheng Chen^*‡, Tzu-Chieh Yin^*§¶, Wei-Chih Su^*‡, Po-Jung Chen^*,Tsung-Kun Chang^*†, Ching-Chun Li^*, Ching-Wen Huang^*†, Jaw-Yuan Wang^{*†‡#**††‡‡}

Oncology Research, Vol.29, No.1, pp. 47-61, 2021, DOI:10.3727/096504022X16451187313084

Abstract Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type metastatic colorectal cancer (mCRC) patients treated with cetuximab or bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation as the first-line therapy. In total, 173 patients with mCRC with RAS wild-type were enrolled. Among them, 98 patients were treated with cetuximab, whereas 75 patients were treated with bevacizumab. All patients received irinotecan dose escalation based on UGT1A1 genotyping. We compared the progression-free… More >

Shuai Liu^*†1, Lu Lu^*†1, Feng Pan^‡, Chunsheng Yang^*†, Jing Liang^§, Jinfeng Liu^¶, Jian Wang^#, Rong Shen^**, Fu-Ze Xin^††, Nan Zhang^*†

Oncology Research, Vol.29, No.1, pp. 25-31, 2021, DOI:10.3727/096504022X16427607626672

Abstract Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival… More >

Pierre-Guillaume Poureau^1,2,*, Estelle Dhamelincourt², Jessica Nguyen², Hélène Babey², Emmanuelle Renaud², Margaux Geier², Michèle Boisdron-Celle³, Jean-Philippe Metges²

Oncologie, Vol.23, No.2, pp. 195-202, 2021, DOI:10.32604/Oncologie.2021.015929 - 22 June 2021

Abstract Introduction: Regorafenib is a multi tyrosin-kinase inhibitor prescribed in metastatic refractory colorectal cancer treatment. Its toxicity is significant but inconstant. The metabolism of regorafenib includes oxydation via cytochrome P3A4, then glucuroconjugation. A pharmacogenetical approach of mutational status of Uridine-Diphospho-Glucuronosyltransfersase (UDP-glucuronosyl-transferase, UGT) could be a strategy to optimise the use of regorafenib. Patients and Method: This is a restrospective, unicentric study. All adult patients treated with regorafenib for a metastatic colorectal cancer in our center between 2013 and 2017 were analysed. UGT1A1 polypmorphism was previously researched in the laboratory after written informed consent. Results: Thirty-five patients… More >

Tsung-Kun Chang^*†, Tzu-Chieh Yin^‡§, Wei-Chih Su^*†, Hsiang-Lin Tsai^*¶, Ching-Wen Huang^*¶, Yen-Cheng Chen^*, Ching-Chun Li^*, Po-Jung Chen^*, Cheng-Jen Ma^*§, Kuo-Hsiang Chuang^#, Tian-Lu Cheng^**, Jaw-Yuan Wang^{*†¶††‡‡§§}

Oncology Research, Vol.28, No.7-8, pp. 801-809, 2020, DOI:10.3727/096504021X16218531628569

Abstract Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecaninduced diarrhea is intestinal mucosal damage caused by SN-38 (active metabolite of irinotecan) hydrolyzed from SN-38G (inactive metabolite) by bacterial -glucuronidase ( G). According to an animal study, silymarin reduces the activity of bacterial G without impairing antitumor efficacy. We conducted a prospective openlabel pilot study to evaluate the effect of silymarin as supplementation in reducing toxicities of mCRC patients undergoing irinotecan-based chemotherapy. We enrolled and randomized More >

Cheng-Jen Ma^*†‡, Ching-Wen Huang^*‡§, Yung-Sung Yeh^*†¶, Hsiang-Lin Tsai^*§#**, Huang-Ming Hu^††‡‡, I-Chen Wu^††‡‡, Tian-Lu Cheng^§§¶¶, Jaw-Yuan Wang^{*†‡§**¶¶}

Oncology Research, Vol.25, No.5, pp. 673-679, 2017, DOI:10.3727/97818823455816X14786040691928

Abstract We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping. Thirteen patients with previously treated mCRC were subjected to UGT1A1 genotyping between October 2013 and June 2015 and were administered regorafenib plus FOLFIRI with irinotecan dose escalation. Patients with UGT1A1*1/*1 and *1/*28 genotypes were administered 180 mg/m² of irinotecan, whereas those with the UGT1A1*28/*28 genotype were administered 120 mg/m2 of irinotecan. For all patients, the irinotecan dose was increased by 30 mg/m2 every… More >